These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11932279)

  • 21. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women.
    Mortola JF; Yen SS
    J Clin Endocrinol Metab; 1990 Sep; 71(3):696-704. PubMed ID: 2144295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women.
    Labrie F; Diamond P; Cusan L; Gomez JL; Bélanger A; Candas B
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3498-505. PubMed ID: 9329392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels.
    Uebelhart B; Herrmann F; Pavo I; Draper MW; Rizzoli R
    J Bone Miner Res; 2004 Sep; 19(9):1518-24. PubMed ID: 15312253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial.
    von Mühlen D; Laughlin GA; Kritz-Silverstein D; Bergstrom J; Bettencourt R
    Osteoporos Int; 2008 May; 19(5):699-707. PubMed ID: 18084691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Dehydroepiandrosterone And WellNess (DAWN) study: research design and methods.
    von Mühlen D; Laughlin GA; Kritz-Silverstein D; Barrett-Connor E
    Contemp Clin Trials; 2007 Feb; 28(2):153-68. PubMed ID: 16784898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dehydroepiandrosterone treatment is not beneficial to the immune response to influenza in elderly subjects.
    Danenberg HD; Ben-Yehuda A; Zakay-Rones Z; Gross DJ; Friedman G
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2911-4. PubMed ID: 9284718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dehydroepiandrosterone supplementation in elderly men: a meta-analysis study of placebo-controlled trials.
    Corona G; Rastrelli G; Giagulli VA; Sila A; Sforza A; Forti G; Mannucci E; Maggi M
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3615-26. PubMed ID: 23824417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology.
    Labrie F; Bélanger A; Cusan L; Candas B
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2403-9. PubMed ID: 9253308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations.
    Forsblad-d'Elia H; Carlsten H; Labrie F; Konttinen YT; Ohlsson C
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2044-51. PubMed ID: 19318446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men.
    Leder BZ; Smith MR; Fallon MA; Lee ML; Finkelstein JS
    J Clin Endocrinol Metab; 2001 Feb; 86(2):511-6. PubMed ID: 11158001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome.
    Cleare AJ; O'Keane V; Miell JP
    Psychoneuroendocrinology; 2004 Jul; 29(6):724-32. PubMed ID: 15110921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men.
    Acacio BD; Stanczyk FZ; Mullin P; Saadat P; Jafarian N; Sokol RZ
    Fertil Steril; 2004 Mar; 81(3):595-604. PubMed ID: 15037408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dehydroepiandrosterone (DHEA) replacement reduces growth hormone (GH) dose requirement in female hypopituitary patients on GH replacement.
    Brooke AM; Kalingag LA; Miraki-Moud F; Camacho-Hübner C; Maher KT; Walker DM; Hinson JP; Monson JP
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):673-80. PubMed ID: 17054472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endocrine effects of oral dehydroepiandrosterone in men with HIV infection: a prospective, randomized, double-blind, placebo-controlled trial.
    Poretsky L; Brillon DJ; Ferrando S; Chiu J; McElhiney M; Ferenczi A; Sison MC; Haller I; Rabkin J
    Metabolism; 2006 Jul; 55(7):858-70. PubMed ID: 16784956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects.
    Legrain S; Massien C; Lahlou N; Roger M; Debuire B; Diquet B; Chatellier G; Azizi M; Faucounau V; Porchet H; Forette F; Baulieu EE
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3208-17. PubMed ID: 10999810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of dehydroepiandrosterone therapy on pubic hair growth and psychological well-being in adolescent girls and young women with central adrenal insufficiency: a double-blind, randomized, placebo-controlled phase III trial.
    Binder G; Weber S; Ehrismann M; Zaiser N; Meisner C; Ranke MB; Maier L; Wudy SA; Hartmann MF; Heinrich U; Bettendorf M; Doerr HG; Pfaeffle RW; Keller E;
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1182-90. PubMed ID: 19126625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older women.
    Kenny AM; Boxer RS; Kleppinger A; Brindisi J; Feinn R; Burleson JA
    J Am Geriatr Soc; 2010 Sep; 58(9):1707-14. PubMed ID: 20863330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
    Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial.
    Hunt PJ; Gurnell EM; Huppert FA; Richards C; Prevost AT; Wass JA; Herbert J; Chatterjee VK
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4650-6. PubMed ID: 11134123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.